Record Display for the EPA National Library Catalog


OLS Field Name OLS Field Data
Main Title Mutagenesis of L5178Y/TK(+/-)-3.7.2C Mouse Lymphoma Cells by the Clastogen Ellipticine.
Author Moore, M. M. ; Brock, K. H. ; Doerr, C. L. ; DeMarini, D. M. ;
CORP Author Health Effects Research Lab., Research Triangle Park, NC. Genetic Toxicology Div. ;Environmental Health Research and Testing, Inc., Research Triangle Park, NC.
Year Published 1987
Report Number EPA/600/J-87/195;
Stock Number PB88-165931
Additional Subjects Lymphoma ; Mice ; Reprints ; Mutagenesis ; Clastogen ellipticine
Library Call Number Additional Info Location Last
NTIS  PB88-165931 Most EPA libraries have a fiche copy filed under the call number shown. Check with individual libraries about paper copy. NTIS 06/21/1988
Collation 13p
The antitumor drug ellipticine is clastogenic in CHO cells (Bhuyan et al., 1972) but is only weakly mutagenic at the hprt locus in CHO cells (DeMarini et al., 1983; Singh and Gupta, 1983a,b). In the present study, the mutagenic and clastogenic activities of ellipticine were evaluated in L5178Y/TK+/- -3.7.2C mouse lymphoma cells. Unlike the results at the hprt locus, ellipticine is a potent mutagen at the tk locus, with as little as 50 ng/ml producing 270 TK-deficient mutants/10 to the 6th power survivors at approx. 50% survival (background = 72/10 to the 6th power survivors). This same dose of ellipticine induced 44 aberrations per 100 metaphases (background = 5/100 cells). At 400 ng/ml, ellipticine induced over 1,000 mutants/10 to the 6th power survivors at approx. 10% survival and produced 242 aberrations/100 cells. Most of the aberrations were chromosome rather than chromatid events. As expected for a compound acting primarily by a clastogenic mechanism, almost all of the TK-deficient mutants were small colonies. Thus, ellipticine is a potent clastogen in both Chinese hamster cells and in mouse lymphoma cells; however, it is a potent mutagen at only the tk locus and not at the hprt locus.